News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Jan 27, 2023 StatementCOVID-19 Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023/2024 Vaccination Season at VRBPAC Meeting Download Jan 25, 2023 Corporate and finance Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) Download Jan 18, 2023 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster Download Jan 9, 2023 Corporate and finance Novavax Names John C. Jacobs as New President & Chief Executive Officer Download Jan 9, 2023 Statement Novavax to Participate in the 41st Annual J.P. Morgan Healthcare Conference Download Jan 5, 2023 Spanish, Italian and French Health Authorities Expand Recommendations for Use of Novavax COVID-19 Vaccine Download Dec 30, 2022 COVID-19Seasonal influenza Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Download Dec 28, 2022 Corporate and finance Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock Download Dec 16, 2022 StatementGlobal healthCOVID-19 German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster Download Dec 15, 2022 Corporate and finance Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes Download Dec 15, 2022 Corporate and finance Novavax Announces Pricing of $65 Million Public Offering of Common Stock Download Dec 14, 2022 Corporate and finance Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes Download Dec 14, 2022 Corporate and finance Novavax Announces Proposed $125 Million Public Offering of Common Stock Download Dec 12, 2022 Statement Swiss and French Health Authorities Expand Recommendations for Use of Nuvaxovid COVID-19 Vaccine as a Booster Download Dec 7, 2022 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents Download Dec 2, 2022 Corporate and finance Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference Download Nov 29, 2022 COVID-19 World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults Download Nov 23, 2022 StatementCOVID-19 Termination of COVID-19 Vaccine Purchase Agreement with Gavi Download Nov 18, 2022 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults Download Nov 14, 2022 Corporate and finance Novavax to Participate in Jefferies London Healthcare Conference Download Nov 9, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults Download Nov 8, 2022 Corporate and finance Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights Download Nov 8, 2022 COVID-19 Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster Download Nov 1, 2022 Corporate and finance Novavax Appoints Rick Rodgers to Board of Directors Download Nov 1, 2022 Corporate and finance Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022 Download Show 5102550100 per page«123456789…18»